 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors considering a purchase of Vericel Corp (VCEL) shares, but tentative about paying the going market price of 51.31/share, might benefit from considering selling puts among the...

Commit To Buy Vericel At $25, Earn 9% Annualized Using Options

Vericel Co. (NASDAQ:VCEL - Get Free Report) Director Robert L. Md Zerbe sold 3,278 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price...

Robert L. Md Zerbe Sells 3,278 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL - Get Free Report) Director Robert L. Md Zerbe sold 3,278 shares of the firm's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of...

Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Shares

SG Americas Securities LLC lowered its stake in Vericel Co. (NASDAQ:VCEL - Free Report) by 36.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 40,405 shares of...

Vericel Co. (NASDAQ:VCEL) Stock Holdings Decreased by SG Americas Securities LLC

Truist Financial reissued their buy rating on shares of Vericel (NASDAQ:VCEL - Free Report) in a research note published on Tuesday morning, Benzinga reports. Truist Financial currently has a $54.00...

Vericel (NASDAQ:VCEL) Earns "Buy" Rating from Truist Financial

Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL)

In recent trading, shares of Vericel Corp (VCEL) have crossed above the average analyst 12-month target price of 50.90, changing hands for 52.33/share. When a stock reaches the target an...

Vericel Reaches Analyst Target Price

This is a Bullish indicator signaling VCEL's price could rise from here. Traders may explore going long the stock or buying call options...

Vericel (VCEL, $46.95) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

This is a signal that VCEL's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Vericel (VCEL, $46.71) Stochastic Oscillator left the overbought zone on March 21, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vericel management to meet with Truist

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Volume (M)	59,228.00
52-Wk High	$53.05
52-Wk Low	$29.24

VCEL Vericel Corp

About

Feed

News

Sentiment

Earnings

Fundamentals